eamdacademy.org-xzRh-1790603951-z586636342 1790603951 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2026 5 2 Luis Herrera Daniela Rojas Andres Castro 2026 10.68159/z586636342 https://eamdacademy.org/pub/journal/3/article/z586636342 Ozawa S, Shankar R, Leopold C, Orubu S. Access to medicines through health systems in low-and middle-income countries. Health Policy Plan. 2019;34(Suppl_3):iii1-3. Braveman P, Arkin E, Orleans T, Proctor D, Acker J, Plough A, et al. What is health equity? Behav Sci Policy. 2018;4(1):1-4. Rodriguez NM, Burleson G, Linnes JC, Sienko KH. Thinking beyond the device: an overview of human-and equity-centered approaches for health technology design. Annu Rev Biomed Eng. 2023;25(1):257-80. Antoñanzas F, Terkola R, Overton PM, Shalet N, Postma M. Defining and measuring the affordability of new medicines: a systematic review. Pharmacoeconomics. 2017;35(8):777-91. Uskoković V. Nanomedicine for the poor: a lost cause or an idea whose time has yet to come? Nanomedicine. 2021;16(14):1203-18. Salamanca-Buentello F, Daar AS. Nanotechnology, equity and global health. Nat Nanotechnol. 2021;16(4):358-61. Delany-Moretlwe S, Flexner C, Bauermeister JA. Advancing use of long-acting and extended delivery HIV prevention and treatment regimens. J Int AIDS Soc. 2023;26(Suppl 2):e26126. Jenkins SY, Resar D, Panos Z, Staple A, Watkins M, Ripin D, et al. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low-and middle-income countries. J Int AIDS Soc. 2023;26:e26101. Seoane-Viano I, Xu X, Ong JJ, Teyeb A, Gaisford S, Campos-Álvarez A, et al. A case study on decentralized manufacturing of 3D printed medicines. Int J Pharm X. 2023;5:100184. Mathew E, Pitzanti G, Larrañeta E, Lamprou DA. 3D printing of pharmaceuticals and drug delivery devices. Pharmaceutics. 2020;12(3):266. Tracy T, Wu L, Liu X, Cheng S, Li X. 3D printing: Innovative solutions for patients and pharmaceutical industry. Int J Pharm. 2023;631:122480. Tase A, Vadhwana B, Buckle P, Hanna GB. Usability challenges in the use of medical devices in the home environment: a systematic review of literature. Appl Ergon. 2022;103:103769. van den Bemt BJ, Gettings L, Domańska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384-92. Lageat C, Combedazou A, Ramus C, Guerrero K, Frolet C, Glezer S. Formative and validation human factors studies of a new disposable autoinjector for subcutaneous delivery of chronic disease therapies. Expert Opin Drug Deliv. 2021;18(11):1761-75. Gashema P, Iradukunda PG, Saramba E, Musafiri T, Umuhoza T, Ndahimana F, et al. Bridging the gap: identifying barriers and strategies for widespread implementation of long-acting injectable antiretroviral therapy in Sub-Saharan Africa: a scoping review. BMC Infect Dis. 2025;25(1):476. Tunis S, Hanna E, Neumann PJ, Toumi M, Dabbous O, Drummond M, et al. Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. Health Policy. 2021;125(12):1550-6. Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, et al. 3D printing technologies in personalized medicine, nanomedicines, and biopharmaceuticals. Pharmaceutics. 2023;15(2):313. Salie F, Saidi T. Nanomedicine drug delivery in South Africa: a retrospective study on research, funding and collaboration. Front Pharmacol. 2024;14:1317137. Iglesias-López C, Agustí A, Vallano A, Obach M. Financing and reimbursement of approved advanced therapies in several European countries. Value Health. 2023;26(6):841-53. Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg JM, Greiner W, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ. 2020;21(9):1421-37. Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018;7(1):15-28. Ogbogu U, Albrecht L. Making advanced therapies affordable and accessible: two strategic approaches. Dev World Bioeth. 2026;26(1):66-78. Conti RM, Demartino P, Gruber J, Lo AW, Sun Y, Wu J. Innovative insurance to improve US patient access to cell and gene therapy. Milbank Q. 2025;103(1):32-51. Chaniaud N, Métayer N, Megalakaki O, Loup-Escande E. Effect of prior health knowledge on the usability of two home medical devices: Usability study. JMIR Mhealth Uhealth. 2020;8(9):e17983. Schneider A, Richard P, Mueller P, Jordi C, Yovanoff M, Lange J. User-centric approach to specifying technical attributes of drug delivery devices: empirical study of autoinjector-cap removal forces. Patient Prefer Adherence. 2021;15:159-68. Tyrrell H, Ravanello R, Pulley J, Tang MT, Zhang W, Abouhossein M, et al. An open-label tolerability and actual-use human factors study of etrolizumab autoinjector in healthy volunteers. Adv Ther. 2021;38(5):2406-17. Bitomsky L, Nißen M, Kowatsch T. Equity by design principles for digital health interventions. Int J Equity Health. 2025;24(1):271. Elbadawi M, McCoubrey LE, Gavins FK, Ong JJ, Goyanes A, Gaisford S, et al. Disrupting 3D printing of medicines with machine learning. Trends Pharmacol Sci. 2021;42(9):745-57. Chandiwana NC, Serenata CM, Owen A, Rannard S, Casas CP, Scott C, et al. Impact of long-acting therapies on the global HIV epidemic. AIDS. 2021;35(Suppl 2):S137-43.